欧林生物:2024年报净利润0.21亿 同比增长16.67%

Financial Performance - The company reported a basic earnings per share of 0.0512 yuan for the 2024 annual report, an increase of 18.24% compared to 0.0433 yuan in 2023 [1] - Total revenue for 2024 was 5.89 billion yuan, reflecting an 18.75% increase from 4.96 billion yuan in 2023 [1] - Net profit for the year was 0.21 billion yuan, up 16.67% from 0.18 billion yuan in the previous year [1] - The return on equity (ROE) improved to 2.24% in 2024 from 1.96% in 2023, marking a 14.29% increase [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 19,962.09 million shares, accounting for 49.25% of the circulating shares, with a decrease of 669.70 million shares compared to the previous period [1] - Shanghai Wushan Biotechnology Co., Ltd. remains the largest shareholder with 7,239.43 million shares, representing 17.86% of the total share capital [2] - The fund "Xingquan Helun Mixed" increased its holdings by 8.61 million shares, while "Zou Long" and "Zhang Yu" reduced their holdings by 250.20 million and 189.00 million shares, respectively [2] Dividend Policy - The company has decided not to distribute dividends or increase capital through share distribution [1]